{"id":"NCT01959295","sponsor":"Maruho Co., Ltd.","briefTitle":"Phase III Study of ASP2151 in Herpes Simplex Patients","officialTitle":"Phase III Study of ASP2151 in Herpes Simplex Patients - A Double-blind, Placebo-controlled Study -","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-08","primaryCompletion":"2015-04","completion":"2015-04-27","firstPosted":"2013-10-10","resultsPosted":"2024-10-09","lastUpdate":"2024-10-09"},"enrollment":468,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Herpes Simplex"],"interventions":[{"type":"DRUG","name":"ASP2151","otherNames":[]},{"type":"DRUG","name":"ASP2151 placebo","otherNames":[]}],"arms":[{"label":"ASP2151","type":"EXPERIMENTAL"},{"label":"ASP2151 placebo","type":"PLACEBO_COMPARATOR"}],"summary":"To evaluate the efficacy and safety of ASP2151 in patients with herpes simplex.","primaryOutcome":{"measure":"Percentage of Participants With Healing by Day 8","timeFrame":"8days","effectByArm":[{"arm":"ASP2151","deltaMin":66.4,"sd":null},{"arm":"ASP2151 Placebo","deltaMin":69.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.5086"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":3,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":309},"commonTop":["Alpha 1 microglobulin increased","Oral herpes","Nasopharyngitis","Fibrin degradation products increased","Genital herpes"]}}